Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG, Allos to merge – but will it really bring sales synergies for Feraheme, Folotyn?

This article was originally published in Scrip

Executive Summary

AMAG Pharmaceuticals said it plans to merge with Allos Therapeutics in an all-stock deal in order to save money and leverage the sales efforts of the two companies, both of which have launched lead products with disappointing US sales. Both firms need to reach a wider audience to deliver for shareholders.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013781

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel